Top FDA and EMA Drug Approvals in the First Half of 2026 - Transforming Health Care

The first half of 2026 witnessed a series of notable regulatory approvals and positive regulatory recommendations from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) across oncology, infectious diseases, immunology, dermatology, neurology, respiratory medicine, and rare genetic disorders. These milestones introduced new treatment options, expanded indications for established therapies, and advanced first-in-class medicines for patients with significant unmet medical needs. From targeted cancer therapies and innovative antiviral agents to novel treatments for autoimmune, neurological, pulmonary, and inherited diseases, these approvals reflect the continued advancement of precision medicine and evidence-based drug development across major global healthcare markets.

AstraZeneca Receives FDA Approval for Truqap in PTEN-Deficient Metastatic Prostate Cancer

On June 12, 2026, AstraZeneca secured U.S. FDA approval for Truqap (capivasertib) in combination with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or androgen pathway modulation-sensitive prostate cancer, identified through an FDA-authorized companion diagnostic test. The approval was supported by findings from the Phase III CAPItello-281 trial, which demonstrated a significant improvement in radiographic progression-free survival compared with placebo. According to T. Alonso-Gordoa et al. (2024), more than 1.46 million new prostate cancer cases and nearly 397,000 deaths were reported globally in 2022, highlighting the importance of precision therapies targeting specific genetic alterations.

Merck & Co., Inc. Expands Kidney Cancer Treatment with Approval of KEYTRUDA-WELIREG Combination

In June 2026, Merck & Co., Inc. obtained FDA approval for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each administered with WELIREG® (belzutifan), for the adjuvant treatment of adults with clear cell renal cell carcinoma (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy. The approval was based on results from the Phase III LITESPARK-022 trial, where the combination reduced the risk of disease recurrence, metastasis, or death by 28%. According to Massive Bio, clear cell RCC represents approximately 75%–80% of all renal cell carcinoma cases, making this approval an important advancement for patients requiring postoperative therapy.

Shionogi's XOCOVA Becomes the First Oral Therapy for Post-Exposure COVID-19 Prevention

In June 2026, Shionogi & Co., Ltd. received FDA approval for XOCOVA® (ensitrelvir) as the first oral treatment indicated for post-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older following exposure to an infected individual. Approval was supported by the Phase III SCORPIO-PEP trial, which demonstrated a 67% reduction in the risk of symptomatic COVID-19 after exposure. By providing an oral preventive option before symptom onset, XOCOVA fills a significant gap in COVID-19 prevention strategies and expands therapeutic options beyond vaccination.

Gilead Achieves First FDA Approval for Chronic Hepatitis Delta Therapy

Gilead Sciences received accelerated U.S. FDA approval for Hepcludex® (bulevirtide-gmod) on May 22, 2026, addressing one of the longest-standing unmet needs in viral liver disease. The therapy became the first and only FDA-approved treatment for chronic hepatitis delta virus (HDV) infection in adults. Approval was supported by positive Phase III MYR301 data demonstrating significant reductions in HDV RNA and normalization of alanine aminotransferase (ALT). According to the World Gastroenterology Organisation, approximately 240 million people were living with chronic hepatitis B during 2024, representing the population at risk for HDV co-infection.

BeOne Medicines Gains Accelerated Approval for Sonrotoclax in Mantle Cell Lymphoma

In May 2026, the FDA granted accelerated approval to BeOne Medicines USA, Inc. for sonrotoclax (Beqalzi) to treat adults with relapsed or refractory mantle cell lymphoma (MCL) who had received at least two prior systemic therapies, including a Bruton's tyrosine kinase inhibitor. The decision was supported by the Phase II BGB-11417-201 study, which reported a 52% overall response rate. According to the Cleveland Clinic, mantle cell lymphoma affects roughly 1 in 200,000 individuals, making the approval especially valuable for patients with limited treatment alternatives.

Merck & Co., Inc. Received Approval for IDVYNSO as a Once-Daily HIV Treatment

Merck & Co., Inc. obtained U.S. FDA approval in April 2026 for IDVYNSO™ (doravirine/islatravir) to treat virologically suppressed adults with HIV-1 infection who have no history of treatment failure or resistance to doravirine. The once-daily, two-drug regimen became the first non-INSTI, tenofovir-free complete oral therapy to demonstrate non-inferior efficacy compared with a standard three-drug regimen in Phase III clinical trials. According to Helena M. Swinkels et al. (2026), 40.8 million people were living with HIV globally at the end of 2024, emphasizing the continued need for simplified long-term treatment strategies.

Biogen Expands SPINRAZA with a High-Dose Regimen for Spinal Muscular Atrophy

In March 2026, Biogen received FDA approval for the High Dose Regimen of SPINRAZA® (nusinersen) for treating pediatric and adult patients with spinal muscular atrophy (SMA). The approval was supported by the Phase II/III DEVOTE trial, which demonstrated statistically significant improvements in motor function while maintaining a safety profile comparable to the approved lower-dose regimen. According to Vishal Misal et al. (2025), SMA affects approximately 1 in every 10,000 live births, reinforcing the importance of expanding therapeutic options for this rare neuromuscular disease.

Denali Therapeutics Receives Approval for AVLAYAH for Hunter Syndrome

Denali Therapeutics received accelerated U.S. FDA approval in March 2026 for AVLAYAH™ (tividenofusp alfa-eknm) to treat the neurological manifestations of Hunter syndrome (MPS II) in eligible pediatric patients. Supported by Phase I/II clinical data, the therapy demonstrated substantial biomarker reductions and became the first brain-penetrant enzyme replacement therapy approved for the disease. According to the Cleveland Clinic, Hunter syndrome affects approximately 1 in every 100,000 to 170,000 male children.

GSK Expands Cholestatic Pruritus in PBC Treatment with Approval of Lynavoy

In March 2026, GSK plc secured FDA approval for Lynavoy (linerixibat) to treat cholestatic pruritus associated with primary biliary cholangitis (PBC) in adults. Supported by the Phase III GLISTEN trial, the therapy demonstrated rapid and sustained relief from severe itching, becoming the first approved treatment for this indication in the United States. According to Pietro Invernizzi et al. (2025), the global prevalence of PBC is approximately 40.2 cases per 100,000 people, highlighting the significance of therapies that directly address one of the disease's most debilitating symptoms.

Johnson & Johnson's ICOTYDE Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis

Johnson & Johnson received U.S. FDA approval in March 2026 for ICOTYDE™ (icotrokinra), the first IL-23 receptor-targeted oral peptide for adults and adolescents with moderate-to-severe plaque psoriasis eligible for systemic therapy or phototherapy. The once-daily therapy demonstrated favorable efficacy and safety across Phase III clinical studies involving approximately 2,500 patients. According to Dr. Harsh Singh et al. (2025), psoriasis has a global prevalence of 1.41%, supporting the continued demand for innovative systemic therapies.

FDA Approves Bristol Myers Squibb's Sotyktu for Active Psoriatic Arthritis

In March 2026, Bristol Myers Squibb received FDA approval for Sotyktu® (deucravacitinib) to treat adults with active psoriatic arthritis, making it the first TYK2 inhibitor approved for this indication. Approval was based on positive findings from the Phase III POETYK PsA-1 and PsA-2 trials, which demonstrated significant improvements in disease activity compared with placebo. According to Stephanie Lembke et al. (2024), the worldwide prevalence of psoriatic arthritis is approximately 112 cases per 100,000 adults, emphasizing the need for innovative therapies capable of improving long-term outcomes.

Lupin Gains European Commission Approval for Ranluspec™ Across Multiple Retinal Diseases

Lupin Limited received European Commission approval for its biosimilar Ranluspec™ (ranibizumab) in February 2026, following a positive opinion from the Committee for Medicinal Products for Human Use. The approval authorizes the therapy for the treatment of neovascular (wet) age-related macular degeneration, diabetic macular edema, proliferative diabetic retinopathy, macular edema following retinal vein occlusion, and choroidal neovascularization. The biosimilar will be commercialized by Sandoz across the European Union, excluding Germany, while Sandoz and Biogaran will jointly market the product in France, improving access to high-quality biologic therapies for eligible patients.

Boehringer Ingelheim Receives FDA Accelerated Approval for Zongertinib in HER2-Mutated Non-Small Cell Lung Cancer

On February 26, 2026, Boehringer Ingelheim Pharmaceuticals, Inc. received U.S. FDA accelerated approval for zongertinib (Hernexeos) to treat adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test. The approval was supported by results from the Phase II Beamion LUNG-1 trial, in which zongertinib achieved an objective response rate (ORR) of 76%, with 64% of responders maintaining a response for at least six months. According to the American Cancer Society, approximately 77% of all lung cancer cases are non-small cell lung cancer (NSCLC), highlighting the importance of expanding targeted treatment options for patients with HER2-mutated advanced disease.

European Commission Approves Cytokinetics’ MYQORZO® for Adults with Obstructive Hypertrophic Cardiomyopathy

Cytokinetics, Incorporated announced on February 17, 2026, that the European Commission (EC) approved MYQORZO® (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The approval was based on positive results from the pivotal Phase 3 SEQUOIA-HCM trial, which demonstrated meaningful improvements in exercise capacity and symptoms. Following the approval, the company plans to commercially launch MYQORZO in Germany during Q2 2026. According to the European Society of Cardiology, hypertrophic cardiomyopathy affects approximately 1 in 500 Europeans, with nearly half of patients having the obstructive form.

STADA and Bio-Thera Secure European Approval for Gotenfia® in Autoimmune Diseases

In February 2026, STADA and Bio-Thera Solutions received European Commission marketing authorization for Gotenfia® (golimumab), a biosimilar to Simponi®, for the treatment of several chronic inflammatory autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. The approval, announced on February 13, 2026, was supported by comprehensive analytical, non-clinical, and clinical evidence demonstrating biosimilarity. Bio-Thera developed and manufactures Gotenfia®, while STADA holds commercialization rights across Europe, with launch preparations underway to expand patient access through increased biosimilar competition.

Conclusion

The FDA and EMA approvals granted between January and June 2026 underscore the rapid pace of pharmaceutical innovation across multiple therapeutic areas. Several first-in-class therapies, expanded indications, and accelerated approvals addressed diseases with substantial unmet medical needs, including rare genetic disorders, chronic viral infections, autoimmune diseases, and multiple forms of cancer. As precision medicine, biologics, and targeted therapies continue to reshape healthcare, these regulatory milestones are expected to improve patient outcomes while setting the stage for additional therapeutic breakthroughs during the remainder of 2026.